StreetAlpha.app
Home › Stocks › CRVO

CervoMed Inc. (CRVO)

$1.52
▼ −8.98%
LAST CLOSE · NOV 17

CervoMed is a Boston biotechnology company developing neflamapimod, an oral drug candidate for age-related brain disorders. It last closed at $1.52 on Nov 17, down 8.98% on the day.

AI Auto Pilots
Is CRVO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$9K
−99.9% vs a year ago
Net income
−$28.5M
−326822.5% margin
EPS (diluted)
−$2.65
Operating margin
−334924.9%
−$29.2M operating income
Valuation
Market cap
$23.0M
15.1M shares
P/E
–
No P/E while losing money
Price to sales
2635.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$6.1M
At Sep 30
Shareholder equity
$17.4M
Shares outstanding
15.1M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $7.1M$7.1MFY2023FY2024: $9.7M$9.7MFY2024FY2025: $4.0M$4.0MFY2025

From CRVO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated CRVO in the past 90 days.
Average 12-month target
No price targets on CRVO in the past 90 days.
Latest rating changes
Canaccord GenuityMaintained
Aug 10Buy$18
HC Wainwright & Co.Reiterated
Jul 9Buy$25
DateFirmActionRatingPrice target
Aug 10Canaccord GenuityMaintainedBuy$18
Jul 9HC Wainwright & Co.ReiteratedBuy$25
Loading…

Technical Analysis

CRVO · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 18% below its 20 day and 52% below its 50 day average. It is 113% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the Pivot S1 at $1.47, and the nearest resistance the Pivot at $1.56.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 15.2%/day
Key levels
$10.0052 week high+557.9%
$3.24200 day average+113.2%
$2.59100 day average+70.4%
$2.3150 day average+52.0%
$2.20Swing high (Nov 12)+44.7%
$1.7920 day average+17.8%
$1.61Pivot R1+5.9%
$1.56Pivot+2.6%
$1.52Last close
$1.47Pivot S1−3.3%
$1.2752 week low−16.4%
$1.27Swing low (Nov 6)−16.4%
Indicators
RSI (14)35.79Weak, oversold below 30Neutral
MACD-0.22Above its signal lineBullish
Stochastic35.9Middle of its rangeNeutral
ADX (14)29.0Trending down
Williams %R-73.1Oversold below −80, overbought above −20Neutral
CCI (20)-58.4Oversold below −100, overbought above 100Neutral
Rate of change−1.9%Change over 10 sessionsBearish
ATR (14)$0.23Typical daily range, 15.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRVO

What happened before

See how CRVO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in CRVO in the last 90 days.

Loading…

See today’s whale options flow across the market →

CRVO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼11 buying vs 19 selling
  • ▼Held by funds -2.8 pts
  • ▼Funds holding -2
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3537−5.4%
In funds' top 10110.0%
Held by funds8.8%11.6%−2.8 pts
New / increased3 / 87 / 9−31.3%
Reduced / sold out14 / 58 / 5+46.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CRVO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRVO is in one of them and how their past CRVO trades turned out.

CRVO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CRVO in an article yet. Here's the latest on the wider market.

About CervoMed

CervoMed is a biotechnology company based in Boston, Massachusetts, that is developing treatments for brain disorders linked to aging. Its lead candidate, neflamapimod, is an oral drug designed to reduce brain inflammation and address problems with communication between nerve cells. The drug is in clinical trials for dementia with Lewy bodies and is also being studied for other neurological conditions, including ALS. The company does not yet have an approved product, and its intended users are patients with these conditions.

Headquarters
Boston, MA